A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
Key claim: A Phase 1 open-label study is evaluating the safety, tolerability, and efficacy of NC525 in patients with advanced myeloid neoplasms.
Abstract
This is an open-label, non-randomized, Phase 1 study to determine the safety and tolerability of NC525. This study will also assess the clinical benefit in subjects with advanced myeloid neoplasms.
Why this matters
NC525 represents a new investigational candidate entering first-in-human evaluation for advanced myeloid neoplasms, expanding the pipeline of novel agents being tested in this difficult-to-treat population. While no efficacy or safety data are yet available, tracking the trial from inception allows the vault to capture early signals as they emerge and contextualize NC525 against the growing list of investigational myeloid therapeutics.